The deadline of the International Myeloma Society's Career Development Award has been extended to January 15, 2021.
The International Myeloma Society is proud to announce a new initiative “IMS Career Development Award”. The IMS anticipates funding grants for young investigators focused on research in the field of plasma cell dyscrasias.
Goal: To foster the development of an academic career of young scientists pursuing research in the field of plasma cell disorders and to promote the development of the next generation of leaders in this field. This award will also encourage interaction between institutions to enhance collaborative research
Request for Application: Applicants should submit the research proposal by January 15, 2021.
Budget. The grant will be an award of up to $75,000 dollars including maximal allowable institutional overhead of 8%. This may include 1 year of salary support for the grantee, budget for visa status adjustment and travel allowance. Applicants may apply for a second year of funding which will be evaluated based on research progress and available funding. The grantee should have a letter of support from an identified mentor willing to host the applicant for the period of the award. It is expected that the hosting laboratory will cover expenses for research consumables, equipment, and animal costs, if proposed. The applicant, if funded will also receive a complementary IMS membership for 1 year.
Eligibility. Applicants must be junior faculty, fellow or scientist with an MD, PhD, or MD, PhD who have not yet established themselves as independent researchers and who plan to have a career in the field of plasma-cell dyscrasias. Women and underrepresented minorities are particularly encouraged to apply. Applicants should not yet have received NIH funding or its international equivalent. Applicants with prior experience in laboratory research are preferred, but previous laboratory experience is not required. The proposed research should be in a different laboratory than the home institution and either the PI of the home or host institution should be an IMS member. The applicant should agree to acknowledge IMS as the funding source in any publication or presentation resulting from this funding. The applicants should provide a progress report at the end of the funding year and respond to periodic surveys from IMS to track career progress.
Research areas. Basic and translational research projects in all areas of plasma-cell dyscrasia are eligible for this proposal. Outcomes research and non-laboratory projects that do not require a stay abroad in a research laboratory do not qualify for full funding but may be considered to receive partial funding.
The research proposal should be total of 5 pages including figures but not including references and should include the following details: Use 0.5 inch margins, single-spaced, Arial 11 font
1. Specific Aims: (maximum 1 page)
2. Research Plan:
a. Background & Significance
c. Preliminary results
d. Experimental Approach including methods and potential problems and solutions as well as statistical considerations.
3. References (25 maximum).
Moreover, the application should include the following additional information.
1. A statement of how the applicant meets the eligibility criteria and provide a rationale for how the research project in the selected laboratory will foster the career of the applicant (<200 words);
2. Applicant’s CV
3. A letter of support from the applicant’s institution (Home Institution PI) that details the anticipated career path.
4. A letter of support from the Principal Investigator of the hosting laboratory including a statement on mentorship, provision of research resources to allow and facilitate the conduct of the proposed research.
5. Hosting Institution’s Principal Investigator CV to reflect his/her qualification as a mentor.
The deadline for submitting applications will be January 15, 2021. Applications should be sent by email to Moira Luthin (firstname.lastname@example.org)
Contact. For additional questions, please contact us at email@example.com
The next International Myeloma Workshop (IMW) will be held in Vienna, Austria.
Please join us September 8-11, 2021
As a response to the current pandemic, the International Myeloma Society Executive Committee has developed the following Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. These recommendations include directions for caring for newly diagnosed, elderly, relapsed/refractory and clinical trial patients. Please follow as appropriate for your practice and patient needs. The International Myeloma Society remains committed to keeping patients and physicians safe while providing care and treatment under these extraordinary circumstances.
Changes to Upcoming Workshops
The IMS has been closely monitoring the public health outbreak of the novel coronavirus COVID-19. In light of domestic and international travel restrictions, and recognizing the critical roles IMS members, faculty, and attendees have in serving the global patient community, the IMS has made the decision to make adjustments to the following workshops:
The 2nd Immune Effector Cell Therapy in MM Workshop in Boston, MA scheduled for August 28-29 will now occur May 7-8, 2021.
No action is required if you have already registered for this workshop. Your registration will be transferred to the new dates. You will receive an email confirming your registration. If you are unable to attend the new dates and wish to cancel your registration, please email firstname.lastname@example.org. All cancellation fees will be waived.
The IMS will continue to monitor the situation for its meeting scheduled to occur later in the year. Further updates will be communicated as details become available for the following meeting:
The IMS would like to thank all of our members, faculty, attendees, and supporters for their cooperation and understanding during this time. Despite this difficult situation, we are working hard to ensure these workshops are a tremendous success.
Should you have any questions, please contact us at email@example.com.
Updated November 18, 2020.